The DOI matches its Crossref record.
Management of adverse events associated with idelalisib treatment: expert panel opinion
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sunitinib, lapatinib, pazopanib, regorafenib, ponatinib, pexidartinib, and idelalisib are targeted drugs that have been assigned box warnings for hepatotoxicity by the United States Food and Drug Administration (FDA) [150,151].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [151]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 18
- 10.1182/blood-2010-03-275305 · DOI
- ZYDELIG (idelalisib tablets). Summary of product characteristics, Gilead Sciences International Ltd, Cambridge, UK, 2014.
- 10.1016/j.cell.2007.06.009 · DOI · Paper page
- 10.1038/nri1056 · DOI
- 10.1074/jbc.272.31.19236 · DOI
- 10.1182/blood-2011-05-352492 · DOI
- 10.1128/MCB.22.24.8580-8591.2002 · DOI
- 10.1038/nature08638 · DOI
- 10.1182/blood-2010-05-284984 · DOI
- 10.1056/NEJMoa1314583 · DOI
- 10.1056/NEJMoa1315226 · DOI
- Flinn I, 2014, Blood, 124, 10.1182/blood.V96.1.71 · DOI
- 10.1053/j.gastro.2010.07.008 · DOI
- 10.1200/JCO.2004.04.132 · DOI
- 10.1517/14740338.2014.888056 · DOI
- Byrd JC, 2012, Am Soc Clin Oncol Educ Book, 32, 691, 10.14694/EdBook_AM.2012.32.75 · DOI
- 10.1182/blood-2010-02-271171 · DOI
- Jin F, 2014, J Clin Oncol, 32
Cited by
Sorted by citations
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Self-citation
Metadata
- Authors
- Coutré, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., Li, D., O’Brien, S. M., Pagel, J. M., Poleski, M. H., Sharman, J. P., Yao, N.-S., & Zelenetz, A. D.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2015-05-19
- Volume
- 56
- Issue
- 10
- Pages
- 2779-2786
- ISSN
- 1042-8194
- 1029-2403
- PMC
- PMC4732460
- Cited by
- 273
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
